Revenue

As Airbus doubles down in China, the partnership between Paris and Beijing reveals a pragmatic model balancing deep economic ties with a bold geopolitical vision.

Starlight is merging its BC multi-family funds. A key regulatory waiver smooths the path, but what does this mean for investors and market governance?

With new funding, Japan's Helical Fusion is racing to build a fusion plant by the 2030s. Can its unique stellarator technology win the clean energy race?

With a high-grade Alaskan asset secured and a $44M war chest, Vizsla Copper is making a bold move in the race for North American resource security.

How has a family-owned flooring store thrived for 55 years against big-box rivals? Mercury Carpet's story is a masterclass in quality and trust.

SoFi's surprise $1.5 billion stock sale sends shares tumbling. Is this a bold play for market dominance or a sign of fintech's increasing capital hunger?

For the seventh year, Aptar is named a top responsible company. Beyond the award, this is a look at how sustained ESG strategy creates a powerful competitive advantage.

With a clear FDA path for its breakthrough drug, Praxis is set to disrupt the stagnant, multi-billion-dollar essential tremor market.

Beyond marble floors, the new luxury is a seamless, secure, and AI-driven transaction. We explore how tech is reshaping high-end property deals.

A Nasdaq firm is using AI real estate software profits to build a massive Solana treasury. Capital Currents unpacks DFDV's radical dual-pronged strategy.

Baxter is buying back billions in debt, a strategic move to clean its balance sheet. But with operational issues mounting, is it enough to win back investors?

After its DMD drug trial sent shares soaring over 370%, Capricor Therapeutics is raising $75M. A look at the high-stakes strategy to fund a breakthrough.

Immunome is using strategic stock grants to lure top talent. We analyze why this move is critical for its pipeline and what it means for investors.

With its CFO departing after a major strategic pivot, AAR CORP. names a 13-year insider as his interim replacement. What does this signal for investors?

At-home dental tech is booming. Discover how companies are using UVC sterilizers and advanced formulas to disrupt the traditional oral care industry.

Virax secured a $5M runway for its Long COVID diagnostics, but the deal's terms reveal a high-stakes gamble involving significant shareholder dilution.

Promising Phase 3 data reveals a novel, organ-sparing laser therapy for a rare cancer, signaling a potential paradigm shift away from radical surgery.

Bitwise appoints a new data VP amid a frenzied AI market. But can one leader bridge the gap between massive spending and measurable business results?

A new luxury A-frame in Missouri wine country did more than just build a rental; it invested $2M into local artisans, creating a new model for tourism.

Newmark poaches a top CBRE executive to lead its Occupier Solutions, aiming for a $2B revenue goal and challenging the industry's established giants.